Industry News
Predicting Responses To Chemotherapy In Common Lung Cancer With The Help Of Newly Identified Biomarker
Jul 30, 2012
Patients with the most common type of lung cancer are notoriously insensitive to chemotherapy drugs, including cisplatin. New findings related to the cellular pathways that regulate responses to cisplatin have now been published by Cell Press in the journal Cell Reports... Read More
Diagnostic Tests Followed By Personalized Medicine
Jul 30, 2012
A new genre of medical tests - which determine whether a medicine is right for a patient's genes - are paving the way for increased use of personalized medicine, according to the cover story in the current edition of Chemical & Engineering News. C&EN; is the weekly newsmagazine of the American Chemical Society, the world's largest scientific society... Read More
Diagnostic Tests Followed By Personalized Medicine
Jul 30, 2012
A new genre of medical tests - which determine whether a medicine is right for a patient's genes - are paving the way for increased use of personalized medicine, according to the cover story in the current edition of Chemical & Engineering News. C&EN; is the weekly newsmagazine of the American Chemical Society, the world's largest scientific society... Read More
New Treatment Strategies For Brain Tumors Likely Following Genome Analysis
Jul 30, 2012
Brain tumors are the primary cause of cancer mortality in children. Even if a cure is possible, young patients often suffer from the stressful treatment which can be harmful to the developing brain. The most common childhood brain tumors are medulloblastoma and pylocytic astrocytoma... Read More
New Treatment Strategies For Brain Tumors Likely Following Genome Analysis
Jul 30, 2012
Brain tumors are the primary cause of cancer mortality in children. Even if a cure is possible, young patients often suffer from the stressful treatment which can be harmful to the developing brain. The most common childhood brain tumors are medulloblastoma and pylocytic astrocytoma... Read More
Outcomes Of Robotic Surgery: Data Presented At Head And Neck Cancer Annual Meeting
Jul 30, 2012
Predictors of disease severity in human papillomavirus-derived head and neck cancer, tobacco use, and the dramatic benefits of robotic surgery in people with head and neck cancer are among landmark research presented by Mount Sinai School of Medicine at the Eighth International Conference on Head and Neck Cancer. The meeting took place from July 21-25, 2012 in Toronto... Read More
Neoadjuvant Chemotherapy More Suitable For Breast Cancer Patients Who Lack RB Gene
Jul 30, 2012
Breast cancer patients whose tumors lacked the retinoblastoma tumor suppressor gene (RB) had an improved pathological response to neoadjuvant chemotherapy, researchers at Thomas Jefferson University Hospital and the Kimmel Cancer Center at Jefferson report in a retrospective study published in a recent online issue of Clinical Cancer Research... Read More
Neoadjuvant Chemotherapy More Suitable For Breast Cancer Patients Who Lack RB Gene
Jul 30, 2012
Breast cancer patients whose tumors lacked the retinoblastoma tumor suppressor gene (RB) had an improved pathological response to neoadjuvant chemotherapy, researchers at Thomas Jefferson University Hospital and the Kimmel Cancer Center at Jefferson report in a retrospective study published in a recent online issue of Clinical Cancer Research... Read More
For Metastatic Melanoma, Should High-Dose Interleukin-2 Continue To Be The Treatment Of Choice?
Jul 29, 2012
Administering high-doses of interleukin-2 (IL-2) has been the preferred treatment for patients with stage IV metastatic melanoma. An article published in the current issue of Cancer Biotherapy and Radiopharmaceuticals, a peer-reviewed journal from Mary Ann Liebert, Inc., explores whether or not this regimen is still the most effective... Read More
For Metastatic Melanoma, Should High-Dose Interleukin-2 Continue To Be The Treatment Of Choice?
Jul 29, 2012
Administering high-doses of interleukin-2 (IL-2) has been the preferred treatment for patients with stage IV metastatic melanoma. An article published in the current issue of Cancer Biotherapy and Radiopharmaceuticals, a peer-reviewed journal from Mary Ann Liebert, Inc., explores whether or not this regimen is still the most effective... Read More
Previous Page Next Page